Enhanced shear-induced platelet aggregation in acute myocardial infarction

Circulation

Volumn 99, Issue 5, 1999, Pages 608-613

  Goto, Shinya ^a   Sakai, Hiroyuki ^a   Goto, Mami ^a   Ono, Miyuki ^a   Ikeda, Yasuo ^b   Handa, Shunnosuke ^a   Ruggeri, Zaverio M ^c  

^a TOKAI UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b KEIO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^c SCRIPPS RESEARCH INSTITUTE   (United States)

Author keywords

Glycoproteins; Platelets; Thrombosis; Von Willebrand factor

Indexed keywords

GLYCOPROTEIN; RISTOCETIN; THROMBIN RECEPTOR; VON WILLEBRAND FACTOR;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; CORONARY ARTERY THROMBOSIS; DISEASE SEVERITY; HEART INFARCTION; HEART MUSCLE REPERFUSION; HUMAN; PATHOGENESIS; PLASMA; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; RISK FACTOR; SHEAR STRESS; THORAX PAIN; THROMBOCYTE AGGREGATION;

EID: 0033537485     PISSN: 00097322     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.CIR.99.5.608     Document Type: Article

References (40)

1. Fuster V, Badimon L, Badimon JJ, Chesebro JH. The pathogenesis of coronary artery disease and the acute coronary syndromes, I. N Engl J Med. 1992;326:242-250.
2. Fuster V, Badimon L, Badimon JJ, Chesebro JH. The pathogenesis of coronary artery disease and the acute coronary syndromes, II. N Engl J Med. 1992;326:310-318.
3. GISSI Group. Effectiveness of intravenous thrombolytic treatment in acute myocardial infarction: Gruppo Italiano per lo Studio della Streptochinasi nell'Infarto Miocardico (GISSI). Lancet. 1986;1:397-402.
4. ISIS-2 (Second International Study of Infarct Survival) Cooperative Group. Randomized trial of intravenous streptokinase, oral aspirin, both, or neither among 17,187 cases of suspected acute myocardial infarction: ISIS-2. Lancet. 1988;2:349-360.
5. Voth E, Tebbe U, Schicha H, Neuhaus KL, Schroder R, for the ISAM Study Group. Intravenous Streptokinase in Acute Myocardial infarction (ISAM) trial: serial evaluation of left ventricular function up to 3 years after infarction estimated by radionuclide ventriculography. J Am Coll Cardiol. 1991;18:1610-1618.
6. Rapaport E. Thrombolysis, anticoagulation, and reocclusion. Am J Cordiol. 1991;68:17E-22E.
7. Haskel EJ, Prager NA, Sobel BE, Abensdshein DR. Relative efficacy of antithrombin compared with antiplatelet agents in accelerating coronary thrombolysis and preventing early reocclusion. Circulation. 1991;83: 1048-1056.
8. Randomized trial of intravenous heparin versus recombinant hirudin for acute coronary syndromes: the Global Use of Strategies to Open Occluded Coronary Arteries (GUSTO) Investigators. Circulation. 1994; 90:1631-1637.
9. EPIC Investigators. Use of a monoclonal antibody directed against the platelet glycoprotein IIb/IIIa receptor in high risk coronary angioplasty. N Engl J Med. 1994;330:956-961.
10. Stony J, Song A, Rusterholtz L, Adelman B. Aurintricarboxylic acid prevents acute rethrombosis in a canine model of arterial thrombosis. Arterioscler Thromb Vasc Biol. 1995;15:359-366.
11. Kroll MH, Hellums JD, McIntire LV, Schafer AI, Moake JL. Platelet and shear stress. Blood. 1996;88:1525-1540.
12. Ikeda Y, Murata M, Goto S. von Willebrand factor-dependent shear-induced platelet aggregation: basic mechanism and clinical implications. Ann N Y Acad Sci. 1997;811:325-336.
13. Ruggeri ZM. von Willebrand factor. J Clin Invest. 1997;99:559-564.
14. Folsom AR, Wu KK, Rosamond WD, Sharrett AR, Chambless LE. Prospective study of hemostatic factors and incidence of coronary heart disease: the Atherosclerosis Risk in Communities (ARIC) study. Circulation. 1997;96:1102-1108.
15. Smith FB, Rumley A, Lee AJ, Leng GC, Fowkes FG, Lowe GD. Haemostatic factors and prediction of ischaemic heart disease and stroke in claudicants. Br J Haematol. 1998;100:758-763.
16. Goto S, Sakai H, Ikeda Y, Handa S. Acute myocardial infarction plasma augments platelet thrombus growth in high shear rates. Lancet. 1997;349: 543-544. Letter.
17. Austen WG, Edwards JE, Frye RL, Gensini GG, Gott VL, Griffith LS, McGoon DC, Murphy ML, Roe BB. A reporting system on patients evaluated for coronary artery disease: report of the Ad Hoc Committee for Grading of Coronary Artery Disease, Council on Cardiovascular Surgery, American Heart Association. Circulation. 1975;51(suppl 4):5-40.
18. Ikeda Y, Handa M, Kawano K, Kamata T, Murata M, Araki Y, Anbo H, Kawai Y, Watanabe K, Itagaki I, Sakai K, Ruggeri ZM. The role of von Willebrand factor and fibrinogen in platelet aggregation under varying shear stress. J Clin Invest. 1991;87:1234-1240.
19. Handa M, Titani K, Holland LZ, Rober JR, Ruggeri ZM. The von Willebrand factor-binding domain of platelet membrane glycoprotein Ib: characterization by monoclonal antibodies and partial amino acid sequence analysis of proteolytic fragments. J Biol Chem. 1986;261: 12579-12585.
20. Goto S, Salomon DR, Ikeda Y, Ruggeri ZM. Characterization of the unique mechanism mediating the shear-dependent binding of soluble von Willebrand factor to platelet. J Biol Chem. 1995;270:23352-23361.
21. Wada H, Tomeoku M, Kuto M, Deguchi K, Shirakawa S. Factor VIII related antigen in malignant disease: discrepancy between enzyme immunoassay (EIA) and quantitative immunoelectrophoresis [in Japanese]. Nippon Kestueki Gakkai Zasshi. 1983;46:977-988.
22. Puri S, Gresham C, Kad KJ. A simple quantitative assay for ristocetin cofactor activity using microtiter plate and ELISA plate reader. Thromb Res. 1984;74:285-291.
23. Ruggeri ZM, Nilsson IM, Lombardi R, Holmberg L, Zimmerman TS. Aberrant multimeric structure of von Willebrand disease (type IIC). J Clin Invest. 1982;70:1124-1127.
24. Tokuue J, Hayashi J, Hata Y, Nakahara K, Ikeda Y. Enhanced platelet aggregability under high shear stress after treadmill exercise in patients with effort angina. Thromb Haemost. 1996;75:833-837.
25. Back CH, Radbill JR, Crawford DW. Analysis of pulsatile viscous blood flow through diseased coronary arteries of man. J Biomech. 1977;10: 339-353.
26. Knight CJ, Panesar M, Wright C, Clarke D, Butowski PS, Patel D, Patrineli A, Fox K, Goodall AH. Altered platelet function detected by flow cytometry: effects of coronary artery disease and age. Arterioscler Thromb Vasc Biol. 1997;17:2044-2053.
27. Sbarouni E, Bradshaw A. Andreotti F, Tuddenham E, Oakley CM, Cleland JG. Relationship between hemostatic abnormalities and neuroendocrine activity in heart failure. Am Heart J. 1994;127:607-612.
28. Goto S, Sakai H, Ikeda Y, Handa S. Arterial thrombosis in heart failure. Lancet. 1997;351:1558-1559. Letter.
29. Ariad S, Dvilansky A, Sobel R, Nathan I. Plasma von Willebrand factor levels and congestive heart failure. J Intern Med. 1991;229:557-558.
30. Jansson JH, Nilsson TK, Johonson O. von Willebrand factor in plasma: a novel risk factor for recurrent myocardial infarction and death. Br Heart J. 1991;66:351-355.
31. Penny WF, Weinstein M, Salzman EW, Ware JA. Correlation of circulating von Willebrand factor levels with cardiovascular hemodynamics. Circulation. 1991;83:1630-1636.
32. Bates ER, Topol EJ. Limitations of thrombolytic therapy for acute myocardial infarction complicated by congestive heart failure and cardiogenic shock. J Am Coll Cardiol. 1991;108:1077-1084.
33. Goto S, Handa S, Takahashi E, Abe S, Ikeda Y. Synergistic effect of epinephrine and shearing on platelet activation. Thromb Res. 1996;84: 351-359.
34. Goto S, Ikeda Y, Murata M, Handa M, Takahashi E, Yoshioka A, Fujimura M, Fukuyama M, Handa S, Ogawa S. Epinephrine augments von Willebrand factor dependent shear-induced platelet aggregation. Circulation. 1992;86:1859-1863.
35. Simoons ML, de Boer MJ, van den Brand MJ, van Miltenburg AJ, Hoorntje JC, Heyndrickx GR, van der Wieken LR, de Bono D, Rutsch W, Schaible TF, Weisman HF, Klootwijk P, Nijssen KM, Stibbe J, Feyter PJ, and the European Cooperative Study Group. Randomized trial of a GP IIb/IIIa platelet receptor blocker in refractory unstable angina. Circulation. 1994;89:596-603.
36. Konstantopoulos K, Kamat SG, Schafer AI, Banez EI, Jordan R, Kleiman NS, Hellums JD. Shear-induced platelet aggregation is inhibited by in vivo infusion of an anti-glycoprotein IIb/IIIa antibody fragment, c7E3 Fab, in patients undergoing coronary angioplasty. Circulation. 1995;91: 1427-1431.
37. Peerschke EIB. The platelet fibrinogen receptor. Semin Hematol. 1985; 22:241-259.
38. Savage B, Saldivar E, Ruggeri ZM. Initiation of platelet adhesion by arrest onto fibrinogen or translocation on von Willebrand factor. Cell. 1996;84:289-297.
39. Alevriadou BR, Moake JL, Turner NA, Ruggeri ZM, Folie BJ, Phillips MD, Shreiber AB, Hrinda ME, McIntire LV. Real-time analysis of shear-dependent thrombus formation and its blockade by inhibitors of von Willebrand factor binding to platelets. Blood. 1996;81:1263-1276.
40. Goto S, Ikeda Y, Saldivar E, Ruggeri ZM. Distinct mechanisms of platelet aggregation as a consequence of different shearing flow conditions. J Clin Invest. 1998;101:479-486.